Exicure (XCUR) Return on Capital Employed (2017 - 2026)
Exicure (XCUR) reported Return on Capital Employed of 98.41% for Q1 2026, down 3780.0% on a YoY basis from 2.67% in Q1 2025, and down 150.29% quarter-over-quarter from 39.32% in Q4 2025.
Exicure (XCUR) Return on Capital Employed (2017 - 2026) Analysis & Trends
Exicure has reported Return on Capital Employed for 10 years, with the latest figure at 98.41% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 3780.0% year-over-year to 98.41%; the trailing twelve-month figure through Mar 2026 stood at 98.41% (down 3780.0% YoY), and the FY2025 full-year result was 39.71%, up 7966.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 98.41%, down from 39.32% in the prior quarter.
- The five-year high for Return on Capital Employed was 39.11% in Q3 2023, with the low at 467.97% in Q3 2022.
- Historically, Return on Capital Employed has averaged 104.75% across 5 years, with a median of 87.67% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 35440 bps — and 2023, when it jumped 50708 bps.
- Exicure's Return on Capital Employed stood at 7.47% in 2022, then tumbled by 1957 bps to 153.73% in 2023, then climbed by 19 bps to 125.17% in 2024, then jumped by 69 bps to 39.32% in 2025, then slumped by 150 bps to 98.41% in 2026.
- The last three Return on Capital Employed figures came in at 98.41% (Q1 2026), 39.32% (Q4 2025), and 67.21% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Exicure | 19.38 Mn | 16.77 Mn | - | -98.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.41% |
| Dec 31, 2025 | -39.32% |
| Sep 30, 2025 | -67.21% |
| Jun 30, 2025 | -64.38% |
| Mar 31, 2025 | -60.61% |
| Dec 31, 2024 | -125.17% |
| Sep 30, 2024 | -87.67% |
| Jun 30, 2024 | -94.74% |
| Mar 31, 2024 | -133.10% |
| Dec 31, 2023 | -153.73% |
| Sep 30, 2023 | 39.11% |
| Jun 30, 2023 | 16.61% |
| Mar 31, 2023 | 6.54% |
| Dec 31, 2022 | -7.47% |
| Sep 30, 2022 | -467.97% |
| Jun 30, 2022 | -261.77% |
| Mar 31, 2022 | -181.53% |
| Dec 31, 2021 | -167.62% |
| Sep 30, 2021 | -113.57% |
| Jun 30, 2021 | -69.53% |